Phaseline

Targets › CTAG2

CTAG2 (Cancer/testis antigen 2): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Dec 2027.

Open in Phaseline: the race on CTAG2, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Hadassah Medical OrganizationHBI 0201-ESO TCRT
Anti-NY-ESO-1 TCR-gene engineered lymphocytes
CTAG2Phase 1Sarcoma, SynovialDec 2027

Conditions

Sarcoma, Synovial (1)

Modalities

mixed (1)

Companies

Hadassah Medical Organization (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.